secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255130
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q3 net loss $76.7M; positive phase 3 TED data, VRDN-008 best-in-class NHP profile
--------------------------------------------------------------------------------

- Q3 net loss $76.7M vs $47.7M YoY; cash $753.2M, net proceeds $243.2M from Sep offering; runway into H2 2027.
- Positive phase 3 THRIVE data for veligrotug in active TED; THRIVE-2 topline expected Dec 2024.
- Initiated phase 3 REVEAL-1 and REVEAL-2 for VRDN-003; topline data anticipated H1 2026.
- VRDN-008 NHP data: 3x half-life vs efgartigimod, 20% deeper IgG reduction; IND planned year-end 2025.
- VRDN-006 IND submission by year-end 2024; proof-of-concept IgG reduction data in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/0001193125-24-255130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524255130/d911553d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer